<DOC>
	<DOCNO>NCT01874171</DOCNO>
	<brief_summary>Oropharyngeal squamous cell carcinoma ( OPSCC ) incidence increase rapidly develop world . This attribute rise Human Papillomavirus ( HPV ) infection . HPV+OPSCC consider distinct disease entity , affect young patient good prognosis follow treatment . Subsequently , patient live considerable side effect several decade . Radiotherapy cetuximab ( Epidermal Growth Factor Receptor-inhibitor ) demonstrate similar efficacy 'platin ' chemoradiotherapy ( current standard treatment contain platinum-based compound ) head neck cancer , potentially less toxic . Results trial use determine optimum treatment debilitate cancer , primary aim decrease toxicity improve quality life HPV+OPSCC patient .</brief_summary>
	<brief_title>Determination Cetuximab Versus Cisplatin Early Late Toxicity Events HPV+ OPSCC</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>American Joint Committee Cancer ( AJCC ) TNM Stage IIIIVa ( T3N0T4N0 , T1N1T4N3 ) oropharyngeal squamous cell carcinoma ( SCC ) tumours Clinical multidisciplinary team decision treat primary curative cisplatin chemoradiotherapy No previous treatment include surgery , except node biopsy diagnostic tonsillectomy Medically fit ( ECOG 0 , 1 2 ) Adequate cardiovascular , haematological , renal hepatic function Age &gt; 18 year Written inform consent give Using adequate contraception [ male female participant ] . Must take contraceptive measure , least three month treatment . Distant metastasis ( i.e . AJCC TNM stage IVc disease ) AJCC TNM Stage T12N0 disease Treated primary radical surgery primary site ( e.g . resection ) Concurrent use CYP3A4 inducer inhibitor . [ A standard course dexamethasone aprepitant prevention cisplatininduced nausea vomiting permit ] Serious cardiac illness medical condition preclude use cisplatin cetuximab [ history clinically significant cardiac disease , serious arrhythmia , significant conduction abnormality ; uncontrolled seizure disorder ; active neurologic disease ; neuropathy great grade 1 ] Patients p16+ tumour also N2b , N2c N3 nodal disease whose lifetime smoke history also 10 pack year ( i.e . risk factor ) . Pregnant lactate Previous treatment cancer cytotoxics , radiotherapy antiEGFR therapy Inadequate renal , haematological liver function [ Absolute neutrophil count &lt; 1,500/mm3 ; platelet count &lt; 100,000/mm3 ; WBC &lt; 3,000/mm3 ; haemoglobin &lt; 9 g/dL . [ Haemoglobin correction transfusion permit . ] Bilirubin &gt; 1.5 time upper limit normal ( ULN ) ; alkaline phosphatase &gt; 2.5 time ULN ; AST ALT &gt; 2.5 time ULN . Creatinine &gt; 1.5 mg/dL ; Creatinine clearance &lt; 60 mL/min ] Patients clinically significant hearing impairment Life expectancy le 3 month Other malignancy within past 3 year except basal cell skin cancer preinvasive carcinoma cervix .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>